| scholarly article | Q13442814 |
| P2093 | author name string | Ajay Goel | |
| C Richard Boland | |||
| Naoshi Nishida | |||
| Alex Vilkin | |||
| Noriaki Tanaka | |||
| Hiromi Sasamoto | |||
| Minoru Koi | |||
| Nagahide Matsubara | |||
| Takeshi Nagasaka | |||
| Sung Kwan Shin | |||
| Matthias Kloor | |||
| Johannes Gebert | |||
| P2860 | cites work | HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers | Q24546185 |
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status | Q28143274 | ||
| Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer | Q28210081 | ||
| Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer | Q28251800 | ||
| A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer | Q28289377 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. | Q33213563 | ||
| CpG island methylator phenotypes in aging and cancer. | Q33765672 | ||
| Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers | Q34170525 | ||
| The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer | Q34433428 | ||
| COBRA: a sensitive and quantitative DNA methylation assay | Q34630070 | ||
| Emerging concepts in colorectal neoplasia | Q34800070 | ||
| Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype | Q34975498 | ||
| BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum | Q35596687 | ||
| CpG island methylation in colorectal adenomas | Q35746792 | ||
| CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations | Q35807863 | ||
| Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample | Q35855515 | ||
| Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. | Q36276940 | ||
| An elaborate pathway required for Ras-mediated epigenetic silencing | Q40062561 | ||
| B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells | Q40577688 | ||
| Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. | Q40584357 | ||
| P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. | Q40667147 | ||
| CIMP, at last. | Q45015606 | ||
| Epigenetic patterns in the progression of esophageal adenocarcinoma | Q46291635 | ||
| Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer | Q46578998 | ||
| Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. | Q48612358 | ||
| Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability | Q52124747 | ||
| High frequency of low-level microsatellite instability in early colorectal cancer. | Q53394671 | ||
| Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. | Q54443055 | ||
| Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. | Q54568648 | ||
| The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. | Q54572656 | ||
| Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. | Q54648210 | ||
| Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer | Q57240062 | ||
| Genetics supersedes epigenetics in colon cancer phenotype | Q57977995 | ||
| APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer | Q80278776 | ||
| Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation | Q81001994 | ||
| Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma | Q81383354 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 1950-60, 1960.e1 | |
| P577 | publication date | 2008-03-08 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer | |
| P478 | volume | 134 |
| Q34777582 | 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. |
| Q35013990 | A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory |
| Q33811768 | Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency |
| Q38117758 | Advanced precancerous lesions (APL) in the colonic mucosa |
| Q30491000 | Analysis of fecal DNA methylation to detect gastrointestinal neoplasia |
| Q37170000 | Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women |
| Q49771879 | BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. |
| Q41056167 | BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer |
| Q54325213 | BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. |
| Q38089897 | Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers |
| Q57763097 | Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma |
| Q34460444 | Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers |
| Q35677409 | Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. |
| Q55314343 | Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. |
| Q55003977 | Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. |
| Q46425070 | Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features |
| Q37827277 | Colorectal Cancer Epigenetics: Complex Simplicity |
| Q33584274 | Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features |
| Q37346219 | DNA methylation and cancer pathways in gastrointestinal tumors |
| Q83767772 | DNA methylation defects in sporadic and hereditary colorectal cancer |
| Q89717427 | DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation |
| Q34254446 | Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma |
| Q33541307 | Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study |
| Q26768471 | Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review |
| Q35652713 | Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations |
| Q33892398 | Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? |
| Q24598045 | Epigenetics of colorectal cancer |
| Q51126026 | Evaluation and identification of factors related to KRAS and BRAF gene mutations in colorectal cancer: A meta-analysis |
| Q50871791 | Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype |
| Q37578728 | Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer |
| Q53228400 | Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. |
| Q38670418 | Genomic and transcriptomic heterogeneity of colorectal tumors arising in Lynch Syndrome |
| Q36606069 | Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer |
| Q37266816 | Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. |
| Q34372543 | Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis |
| Q37581999 | Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation |
| Q92895821 | Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas |
| Q92423757 | Integrative analysis identifies DNMTs against immune-infiltrating neutrophils and dendritic cells in colorectal cancer |
| Q46255928 | Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma |
| Q33986593 | Malignant melanoma arising from a perianal fistula and harbouring a BRAFgene mutation: a case report |
| Q24627393 | Microsatellite instability in colorectal cancer |
| Q82581451 | Microsatellite instability: Detection and management in sporadic colorectal cancer |
| Q37708015 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. |
| Q26785725 | Molecular phenotypes of colorectal cancer and potential clinical applications |
| Q46352194 | Molecular targets for colon cancer. VEGF, EGFR - and what else? |
| Q34358286 | Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer |
| Q34432116 | Pathogenesis and management of serrated polyps: current status and future directions |
| Q54290348 | Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability |
| Q55533384 | Post-Transplant Rectal Lymphoma After Subtotal Colectomy for Lynch Syndrome–Associated Colorectal Adenocarcinoma. |
| Q35729861 | Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 |
| Q51603737 | Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers |
| Q90746114 | Promoter Hypermethylation of CHODL Contributes to Carcinogenesis and Indicates Poor Survival in Patients with Early-stage Colorectal Cancer |
| Q37245289 | Promoter methylation in the genesis of gastrointestinal cancer |
| Q37688580 | RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis |
| Q40176504 | RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers. |
| Q36411112 | Relationship Between Human mutL Homolog 1 (hMLH1) Hypermethylation and Colorectal Cancer: A Meta-Analysis. |
| Q24610838 | Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications |
| Q26827208 | Serrated lesions of the colorectum: review and recommendations from an expert panel |
| Q33795280 | Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers |
| Q35801395 | The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells |
| Q37889461 | The molecular biology of colorectal carcinoma and its implications: A review |
| Q35552209 | The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case |
| Q37445275 | Toward a comprehensive and systematic methylome signature in colorectal cancers |
| Q37821085 | Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes |
| Q90697948 | Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer |
| Q45823160 | p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers |
Search more.